POTS and Inflammation: Autonomic Dysfunction and the Immune Connection

Postural orthostatic tachycardia syndrome, or POTS, is a form of dysautonomia in which standing up triggers an excessive increase in heart rate, typically a rise of at least 30 beats per minute in adults, without a matching drop in blood pressure. The result is a cluster of disabling symptoms: lightheadedness, palpitations, brain fog, fatigue, exercise intolerance, and sometimes fainting. POTS predominantly affects women, often begins in adolescence or early adulthood, and can be profoundly limiting even though routine bloodwork and cardiac testing frequently come back normal.

For years POTS was framed narrowly as a problem of blood volume, deconditioning, or nervous system wiring. That picture is expanding. A striking feature of POTS is how often it emerges after an infection, and a growing literature now points toward autoimmune and inflammatory mechanisms in a meaningful subset of patients. Understanding this immune dimension helps explain why POTS clusters with other post-viral and inflammatory conditions, and why C-reactive protein and other standard markers so often fail to capture what is happening.

The Autonomic Disorder Behind the Racing Heart

What actually goes wrong on standing. When a healthy person stands, gravity pulls roughly half a liter of blood into the lower body. The autonomic nervous system responds instantly by constricting blood vessels and modestly raising heart rate to maintain blood flow to the brain. In POTS, this reflex is dysregulated. Blood vessels in the lower body often fail to constrict adequately, blood pools, and the heart compensates by beating far faster than it should. The brain, meanwhile, is transiently underperfused, producing the dizziness and cognitive fog that define the experience.

A syndrome with several subtypes. POTS is not a single disease but an umbrella describing a shared physiological signature. Clinicians often distinguish a neuropathic form, in which small autonomic nerve fibers regulating blood vessels are damaged, from a hyperadrenergic form, in which the body overproduces norepinephrine and drives an exaggerated sympathetic response. Many patients also have low blood volume. Importantly, these subtypes are not mutually exclusive, and an inflammatory or autoimmune process can plausibly contribute to more than one of them at once.

Why standard testing looks normal. The core diagnostic tool for POTS is not a blood test but a tilt-table test or an active stand test that measures heart rate and blood pressure with position changes. Because the disorder lives in the nervous system and its receptors rather than in gross tissue damage, markers of systemic inflammation are frequently unremarkable. This mismatch between severe symptoms and normal labs is one reason POTS patients are so often dismissed, and one reason the immune hypothesis has taken time to gain traction.

Autoantibodies and the Autoimmune Hypothesis

Antibodies against the receptors that control circulation. One of the most compelling threads in POTS research is the discovery of autoantibodies targeting G-protein-coupled receptors that regulate cardiovascular function. Studies have reported antibodies directed at adrenergic receptors, which govern how blood vessels constrict and how the heart responds to sympathetic signals, as well as at muscarinic acetylcholine receptors. Antibodies that block or overstimulate these receptors could directly produce the impaired vessel constriction and exaggerated heart-rate response seen in POTS.

An immune fingerprint, not classic inflammation. This kind of autoimmunity is receptor-specific and functional rather than destructive, which distinguishes it from the broad tissue inflammation that raises CRP in conditions like rheumatoid arthritis. The immune system here is not necessarily flooding the blood with inflammatory signals; it is producing targeted antibodies that interfere with autonomic signaling. This helps explain why many POTS patients feel systemically unwell yet show little on conventional inflammatory panels, and why researchers increasingly describe a subset of POTS as an autoimmune channelopathy of the autonomic nervous system.

Evidence is still emerging. It is important to be measured about this science. Autoantibody findings have not been perfectly consistent across laboratories, assays are still being standardized, and the presence of an autoantibody does not by itself prove it is causing disease. What can be said fairly is that multiple independent research groups have found immune abnormalities in POTS cohorts, that these findings align with the clinical pattern of post-infectious onset, and that autoimmune POTS is now a serious and actively investigated hypothesis rather than a fringe idea.

The Post-Viral Trigger: Long COVID and Beyond

Infection as an ignition point. A large fraction of POTS cases begin in the weeks or months after a viral illness, and this timing is central to the inflammatory story. Infections can trigger autoimmunity through molecular mimicry, in which antibodies raised against a pathogen cross-react with the body's own receptors, and through a burst of inflammatory signaling that damages small autonomic nerve fibers. Once the acute infection clears, the autonomic dysfunction can persist long after the virus is gone, sustained by a lingering immune response.

The Long COVID connection. The COVID-19 pandemic dramatically increased attention on POTS because so many people developed it after even mild infections. POTS is now recognized as one of the most common cardiovascular manifestations of Long COVID, and the overlap has accelerated research into how a viral trigger produces durable autonomic and immune dysfunction. The shared features are hard to ignore: post-viral onset, disabling fatigue, exercise intolerance, brain fog, and standard tests that often look reassuringly normal.

Overlap with MCAS and connective tissue conditions. POTS also clusters with mast cell activation syndrome and with hypermobility spectrum disorders such as hypermobile Ehlers-Danlos syndrome. Mast cells release histamine and inflammatory mediators that can dilate blood vessels and destabilize heart rate, offering a direct route from immune activation to autonomic symptoms. Many patients carry two or all three of these diagnoses together, forming a recognizable triad that points toward a shared underlying vulnerability involving the immune system, connective tissue, and autonomic regulation. This overlap reinforces why POTS is best understood not in isolation but as part of a broader landscape of low-grade immune dysregulation.

Where CRP and Monitoring Fit In

A normal CRP does not rule out immune involvement. Because the autoimmune mechanisms in POTS are receptor-targeted rather than broadly inflammatory, C-reactive protein is frequently normal even in patients whose disease is immune-driven. This is a crucial expectation to set. CRP is a sensitive but nonspecific marker of systemic inflammation; it rises with infection, tissue injury, and broad inflammatory disease, but it is not designed to detect the subtle, targeted autoimmunity that characterizes much of POTS. A normal reading should reassure without being interpreted as proof that the immune system is uninvolved.

Where tracking still adds value. That does not make inflammation monitoring pointless. Many POTS patients live with overlapping conditions, recurrent infections, or flares that do involve measurable systemic inflammation, and a rising CRP can flag an intercurrent infection or an inflammatory episode worth discussing with a clinician. Tracking a personal baseline over time, rather than reading a single number in isolation, is where at-home monitoring is most useful, helping distinguish a stable chronic state from an acute change.

Managing the inflammatory contribution. Treatment of POTS is individualized and centers on measures like increased fluid and salt intake, compression garments, careful reconditioning exercise, and medications that modulate heart rate or blood volume. For patients with a clear autoimmune or mast cell component, clinicians may add targeted approaches under specialist care. Layering in general anti-inflammatory habits, prioritizing sleep, managing stress, and following an unprocessed whole-food diet, supports overall immune balance and can complement medical management, even though these steps are not a cure. Any monitoring or lifestyle change should be pursued alongside a knowledgeable healthcare provider, since POTS demands genuinely individualized care.